循環器ジャーナル71巻4号

2023年10月発行

特集 変革期を迎えた肺高血圧症—次世代の病態理解，診断，治療とは？ Ⅲ.肺高血圧症における最新トピックス

肺高血圧症に関する最新の臨床研究

著者： 佐藤希美¹

所属機関： ¹筑波大学医学医療系循環器内科

ページ範囲：P.591 - P.596

POINT
●従来の肺高血圧症治療薬に代わる薬剤としてTGF-β/BMPRⅡ経路に作用するsotaterceptが開発され，その有効性が海外の第Ⅱ・第Ⅲ相試験で示されている．
●肺腫瘍血栓性微小血管症は腺癌に合併する重篤な肺高血圧症であり，チロシンキナーゼ阻害薬によるPDGF・VEGFシグナリング経路の制御の有効性を明らかにするための臨床研究が進行中である．

参考文献

1）Hoeper MM, Badesch DB, Ghofrani HA, et al. Phase 3 Trial of Sotatercept for Treatment of Pulmonary Arterial Hypertension. N Engl J Med 2023 ; 388 : 1478-90.

2）日本循環器学会，日本肺高血圧・肺循環学会，日本呼吸器学会，他．肺高血圧症治療ガイドライン（2017年改訂版）．2018

3）Humbert M, McLaughlin V, Gibbs JSR, et al. Sotatercept for the Treatment of Pulmonary Arterial Hypertension. N Engl J Med 2021 ; 384 : 1204-15.

4）Humbert M, McLaughlin V, Gibbs JSR, et al. Sotatercept for the treatment of pulmonary arterial hypertension : PULSAR open-label extension. Eur Respir J 2023 ; 61 : 2201347.

5）Chung L, Farber HW, Benza R, et al. Unique predictors of mortality in patients with pulmonary arterial hypertension associated with systemic sclerosis in the REVEAL registry. Chest 2014 ; 146 : 1494-504.

6）Ebata S, Yoshizaki A, Oba K, et al. Safety and efficacy of rituximab in systemic sclerosis（DESIRES） : open-label extension of a double-blind, investigators-initiated, randomised, placebo-controlled trial. Lancet Rheumatol 2022 ; 4 : e546-55.

7）Zamanian RT, Badesch D, Chung L, et al. Safety and Efficacy of B-Cell Depletion with Rituximab for the Treatment of Systemic Sclerosis-associated Pulmonary Arterial Hypertension : A Multicenter, Double-Blind, Randomized, Placebo-controlled Trial. Am J Respir Crit Care Med 2021 ; 204 : 209-21.

8）Zhang Y, Michelakis ED. A Phase-2 NIH-sponsored Randomized Clinical Trial of Rituximab in Scleroderma-associated Pulmonary Arterial Hypertension Did Not Reach Significance for Its Endpoints : End of Story? Not So Fast! Am J Respir Crit Care Med 2021 ; 204 : 123-5.

9）Oudiz R, Meyer C, Chin M, et al. Initial Data Report from “LARIAT” : A Phase 2 Study of Bardoxolone Methyl in PAH Patients on Stable Background Therapy. Chest 2015 ; 148（4 Suppl） : 639A.

10）Bardoxolone Methyl in Patients With Connective Tissue Disease-associated Pulmonary Arterial Hypertension-CATALYST ; 2016 Jan 15. ClinicalTrials.gov Identifier : NCT02657356. https://classic.clinicaltrials.gov/ct2/show/NCT02657356（2023年8月閲覧）

11）Qaiser KN, Tonelli AR. Novel Treatment Pathways in Pulmonary Arterial Hypertension. Methodist Debakey Cardiovasc J 2021 ; 17 : 106-14.

12）Price LC, Seckl MJ, Dorfmüller P, et al. Tumoral pulmonary hypertension. Eur Respir Rev 2019 ; 28 : 180065.

13）Godbole RH, Saggar R, Kamangar N. Pulmonary tumor thrombotic microangiopathy : a systematic review. Pulm Circ 2019 ; 9 : 2045894019851000.

14）Ogawa A, Yamadori I, Matsubara O, et al. Pulmonary tumor thrombotic microangiopathy with circulatory failure treated with imatinib. Intern Med 2013 ; 52 : 1927-30.

15）Kubota K, Shinozaki T, Imai Y, et al. Imatinib dramatically alleviates pulmonary tumour thrombotic microangiopathy induced by gastric cancer. BMJ Case Rep 2017 ; 2017 : bcr2017221032.

16）Minatsuki S, Miura I, Yao A, et al. Platelet-derived growth factor receptor-tyrosine kinase inhibitor, imatinib, is effective for treating pulmonary hypertension induced by pulmonary tumor thrombotic microangiopathy. Int Heart J 2015 ; 56 : 245-8.

）の薬理学的特性および臨床成績．日薬理誌2017 ; 150 : 54-61．